Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 3-10

  Belz, Gustav G ^a  

^a ZeKaPha GmbH   (Germany)

Author keywords

Angiotensin II; AT1 antagonist; Dose effect curves; Pharmacodynamics; Renin angiotensin aldosterone system; Schild regression plot

Indexed keywords

ANGIOTENSIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMBUSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; REGRESSION ANALYSIS; REVIEW; SCHILD REGRESSION; STATISTICAL ANALYSIS;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS;

EID: 0037660850     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01880.x     Document Type: Review

References (39)

1. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
2. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
3. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
4. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
5. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2002; 359: 990-992.
6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
7. 1 antagonists irbesartan and candesartan basing on angiotensin II dose-response in humans. J Cardiovasc Pharmacol 2002; 39: 561-568.
8. Kirch W, Horn B, Schweizer J. Comparison of angiotensin 1I receptor antagonists. Eur J Clin Invest 2001; 31: 698-706.
9. Black J. Heinz Otto Schild, biographic memoirs. London: Royal Society, 1993; 383-415.
10. Belz GG, Essig J, Wellstein A. Hemodynamic response to angiotensin I in normal volunteers and the antagonism by the ACE-inhibitor cilazapril. J Cardiovasc Pharmacol 1987; 9: 219-224.
11. Wellstein A, Belz GG, Palm D. Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans: evaluation with Schild plots. J Exp Pharmacol Ther 1988; 246: 328-337.
12. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959; 14: 48-58.
13. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956; 11: 379-393.
14. 2, a new scale for the measurement of drug antagonism. Br J Pharmacol 1947; 2: 189-206.
15. Malerczyk C, Fuchs B, Belz GG et al. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Br J Clin Pharmacol 1998; 45: 567-573.
16. Gaddum JH. Theories of drug antagonism. Pharmacol Rev 1957; 9: 211-218.
17. Wellstein A, Essig J, Belz GG. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers. Clin Pharmacol Ther 1987; 41: 639-644.
18. Wellstein A, Essig J, Belz GG. A method for estimating the potency of angiotensin-converting enzyme inhibitors in man. Br J Clin Pharmacol 1987; 24: 397-399.
19. Essig J, Belz GG, Wellstein A. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. Br J Clin Pharmacol 1989; 27: 217S-223S.
20. Belz GG, Beermann C, Schloos J, Kleinbloesem CH. The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins. Br J Clin Pharmacol 1989; 28: 608-611.
21. Breithaupt-Grögler K, Malerczyk C, Belz GG et al. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist: characterization by use of Schild regression technique in man. Int J Clin Pharmacol Ther 1997; 35: 434-441.
22. Muller P, Cohen T, De Gasparo M et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
23. Mazzolai L, Maillard M, Rossat J et al. Angiotensin II receptor blockade in normotensive subjects; a direct comparison of three AT-1 receptor antagonists. Hypertension 1999; 33: 850-855.
24. Ribstein J, Picard A, Armagnac C et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects. J Hypertens 1997; 15 (Suppl 4): S117-S118.
25. Morgan JM, Palmisano M, Piraino A et al. The effect of vasartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 1997; 61: 35-44.
26. Wellstein A, Palm D, Pitschner HF et al. Receptor binding of propranolol is the missing link between plasma concentrations kinetics and effect-time course in man. Eur J Clin Pharmacol 1985; 29: 131-147.
27. Morsing P, Adler G, Brandt-Eliasson U et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.
28. 1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol 1999; 367: 413-422.
29. 1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 1999; 372: 199-206.
30. 1 antagonists assessed by Schild regression technique in man. JRAAS 2000; 1: 336-341.
31. Gossmann J, Burkhardt R, Harder S et al. Effect of angiotensin II infusion with and without angiotensin II type receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers. Clin Pharmacol Ther 2000; 68: 501-509.
32. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33 (Suppl 1): S21-S28.
33. Iyer SN, Chappell MC, Averill DB et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705.
34. Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of Iosartan. Role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776.
35. Belz GG, Butzer R, Kober S et al. Time course and extent of Angiotensin II antagonism following Irbesartan, Losartan and Valsartan in humans assessed by angiotensin II dose-response and radioligand receptor assay. Clin Pharmacol Ther 1999; 66: 367-373.
36. 2: application to the analgesic effect of morphine. J Pharmacol Exp Ther 1978; 206: 38-45.
37. Holford NHG, Sheiner LB. Kinetics of' pharmacologic response. Pharmacol Ther 1982; 16: 143-166.
38. Sheiner LB, Stanski DR, Vozeh S et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
39. Conlin PR, Spence DJ, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.